These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34990002)

  • 1. Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials.
    Sholter D; Wu J; Jia B; Zhang H; Griffing K; Birt J; Reis PJS; Liu H; Bingham CO
    Rheumatol Ther; 2022 Apr; 9(2):541-553. PubMed ID: 34990002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
    Smolen JS; Kremer JM; Gaich CL; DeLozier AM; Schlichting DE; Xie L; Stoykov I; Rooney T; Bird P; Sánchez Bursón JM; Genovese MC; Combe B
    Ann Rheum Dis; 2017 Apr; 76(4):694-700. PubMed ID: 27799159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study.
    Wells AF; Jia B; Xie L; Valenzuela GJ; Keystone EC; Li Z; Quebe AK; Griffing K; Otawa S; Haraoui B
    Rheumatol Ther; 2021 Jun; 8(2):987-1001. PubMed ID: 34028703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
    Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
    Strand V; Schiff M; Tundia N; Friedman A; Meerwein S; Pangan A; Ganguli A; Fuldeore M; Song Y; Pope J
    Arthritis Res Ther; 2019 Dec; 21(1):263. PubMed ID: 31791386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.
    Kremer JM; Schiff M; Muram D; Zhong J; Alam J; Genovese MC
    RMD Open; 2018; 4(1):e000581. PubMed ID: 29479473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
    Strand V; Kaine J; Alten R; Wallenstein G; Diehl A; Shi H; Germino R; Murray CW
    Arthritis Res Ther; 2020 Oct; 22(1):243. PubMed ID: 33059710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib
    Yang Y; Xu J; Xu J; Li X; Hu J; Li X; Zhang X; He D; Bao C; Li Z; Wang G; Zerbini CAF; Spindler AJ; Kannowski CL; Wu H; Ji F; Zhan L; Liu M; Li Z
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006964. PubMed ID: 33959198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.
    Emery P; Blanco R; Maldonado Cocco J; Chen YC; Gaich CL; DeLozier AM; de Bono S; Liu J; Rooney T; Chang CH; Dougados M
    RMD Open; 2017; 3(1):e000410. PubMed ID: 28405473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative Impact of Pain and Disease Activity on Improvements in Fatigue: Results From 2 Baricitinib Phase 3 Clinical Trials.
    Fautrel B; Wu J; Wang D; Haladyj E; van de Laar MAFJ; Takeuchi T
    J Clin Rheumatol; 2023 Apr; 29(3):139-144. PubMed ID: 36473106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.
    Wells AF; Greenwald M; Bradley JD; Alam J; Arora V; Kartman CE
    Rheumatol Ther; 2018 Jun; 5(1):43-55. PubMed ID: 29680881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
    Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy Of Baricitinib in Patients With Moderate-To-Severe Rheumatoid Arthritis Up to 6.5 Years Of Treatment: Results Of A Long-Term Study.
    Caporali R; Taylor PC; Aletaha D; Sanmartí R; Takeuchi T; Mo D; Haladyj E; Bello N; Zaremba-Pechmann L; Fang Y; Dougados M
    Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38258434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
    Strand V; Pope J; Tundia N; Friedman A; Camp HS; Pangan A; Ganguli A; Fuldeore M; Goldschmidt D; Schiff M
    Arthritis Res Ther; 2019 Dec; 21(1):272. PubMed ID: 31815649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
    Taylor PC; Chen YF; Pope J; Weinblatt M; Mysler E; Rubbert-Roth A; Jia B; Sun L; Liu Y; Holzkämper T; Tanaka Y
    Rheumatol Ther; 2023 Apr; 10(2):463-476. PubMed ID: 36662442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib.
    Pope JE; Lee YC; Curtis JR; Mo D; Xie L; Dickson CL; Schlichting DE; Cardoso A; Simon LS; Taylor PC
    ACR Open Rheumatol; 2022 Mar; 4(3):254-258. PubMed ID: 34913611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
    Bingham CO; Walker D; Nash P; Lee SJ; Ye L; Hu H; Khalid JM; Combe B
    Arthritis Res Ther; 2022 Jan; 24(1):11. PubMed ID: 34980223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1.
    Strand V; Mease PJ; Soriano ER; Kishimoto M; Salvarani C; Saffore CD; Zueger P; McDearmon-Blondell E; Kato K; Gladman DD
    Rheumatol Ther; 2021 Dec; 8(4):1789-1808. PubMed ID: 34636026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.